共 50 条
- [1] The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer[J]. NATURE, 2024, 629 (8014) : 1142 - 1148Abraham, Jean E.Pinilla, KarenDayimu, AlimuGrybowicz, LouiseDemiris, NikolaosHarvey, CaronDrewett, Lynsey M.Lucey, RebeccaFulton, AlexanderRoberts, Anne N.Worley, Joanna R.Chhabra, AnitaQian, WendiVallier, Anne-LaureHardy, Richard M.Chan, SteveHickish, TamasTripathi, DevashishVenkitaraman, RamachandranPersic, MojcaAslam, ShahzeenaGlassman, DanielRaj, SanjayBorley, AnnabelBraybrooke, Jeremy P.Sutherland, StephanieStaples, EmmaScott, Lucy C.Davies, MarkPalmer, Cheryl A.Moody, MargaretChurn, Mark J.Newby, Jacqueline C.Mukesh, Mukesh B.Chakrabarti, AmitabhaRoylance, Rebecca R.Schouten, Philip C.Levitt, Nicola C.Mcadam, KarenArmstrong, Anne C.Copson, Ellen R.Mcmurtry, EmmaTischkowitz, MarcProvenzano, ElenaEarl, Helena M.
- [2] Neoadjuvant treatments for triple-negative breast cancer (TNBC)[J]. ANNALS OF ONCOLOGY, 2012, 23 : 35 - 39von Minckwitz, G.Martin, M.
- [3] Neoadjuvant olaparib monotherapy in primary triple negative breast cancer[J]. ANNALS OF ONCOLOGY, 2019, 30Eikesdal, H. P.Yndestad, S.Blix, E. S.Lundgren, S.Vagstad, G.Espelid, H.Gilje, B.Janssen, E. A.Geisler, J.Aas, T.Aase, H.Knappskog, S.Lonning, P. E.
- [4] Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Ryan, P. D.Tung, N. M.Isakoff, S. J.Golshan, M.Richardson, A.Corben, A. D.Smith, B. L.Gelman, R.Winer, E. P.Garber, J. E.
- [5] Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer[J]. CANCER RESEARCH, 2022, 82 (04)Im, Seock-AhLee, Kyung-HunMin, AhrumLee, DaewonKim, Tae YongRyu, Han SukKoh, JiwonCheon, Gi-JeongShin, Yoon-JungKim, YujinMoon, Hyeong-GonHan, WonshikLee, Han-ByoelDiolaiti, MorganQuigley, DavidAshworth, AlanCho, Nariya
- [6] Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial[J]. JAMA ONCOLOGY, 2022, 8 (12) : 1802 - 1808Loap, PierreLoirat, DelphineBerger, FrederiqueRodrigues, ManuelBazire, LouisPierga, Jean-YvesVincent-Salomon, AnneLaki, FatimaBoudali, LatifaRaizonville, LaurenceMosseri, VeroniqueJochem, AnneEeckhoutte, AlexandreDiallo, MamadouStern, Marc-HenriFourquet, AlainKirova, Youlia
- [7] A promising combination partner for paclitaxel in triple-negative breast cancer (TNBC) therapy[J]. CANCER RESEARCH, 2022, 82 (12)Lee, Youl-NamHan, Yun-heeKim, Won-SamLee, Cheol-MinMoon, Eun-JoungKim, Hae-Jin
- [8] Early prediction of response to Neoadjuvant Immunotherapy in Triple Negative Breast Cancer (TNBC) with DCEMRI[J]. CANCER RESEARCH, 2024, 84 (09)Rauch, GaianeGuirguis, MaryPatel, MiralCandelaria, RosalindMohamed, RaniaMoseley, TanyaLe-Petross, H. T. CarisaLeung, JessicaWhitman, GaryLane, DeannaScoggins, MarionPerez, FrancesSun, JiaPashapoor, SanazXu, ZhanWhite, JasonWei, PengReed, BrandySon, Jong BumHwang, Ken-PinPanthi, BikashKorkut, AnilHuo, LeiHunt, KellyClayborn, AlysonLitton, JenniferValero, VicenteTripathy, DebuYam, ClintonYang, WeiMa, JingfeiAdrada, Beatriz
- [9] Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC).[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Yam, ClintonAlatrash, GheathYen, Er-YenGarber, HavenPhilips, Anne V.Huo, LeiYang, FeiBassett, Roland L.Sun, XiangjieCuentas, Edwin Roger ParraSymmans, William FraserSeth, SahilWhite, Jason B.Rauch, Gaiane M.Damodaran, SenthilLitton, Jennifer KeatingWargo, Jennifer AnnHortobagyi, Gabriel N.Moulder, Stacy L.Mittendor, Elizabeth A.
- [10] Clinical and pathological response to neoadjuvant chemotherapy (NCT) in patients with triple negative breast cancer (TNBC)[J]. BREAST, 2021, 56 : S52 - S52Krivorotko, P.Zhiltsova, E.Gigolaeva, L.Emelyanov, A.Pesotsky, R.Ereschenko, S.Levsghenko, V.Nikolaev, K.Komayachov, A.Ivanova, O.Tabagua, T.Zernov, K.Ivanov, V.Aseeva, Z.Bessonov, A.Semiglazov, V.